Literature DB >> 26897292

Early experience of percutaneous paravalvular leak closure using a novel Occlutech occluder.

Omer Goktekin1, Mehmet Akif Vatankulu, Hakan Ozhan, Yasin Ay, Mehmet Ergelen, Abdurrahman Tasal, Cemalettin Aydin, Ziya İsmail, İsmail Ates, Ziyad Hijazi.   

Abstract

AIMS: Paravalvular regurgitation is an important complication of mitral valve replacement. Although surgical repair is mostly recommended, it is associated with significant morbidity. On the other hand, percutaneous closure is a less invasive alternative approach. Percutaneous approaches to treatment of paravalvular prosthetic regurgitation have emerged recently. One of them is the Occlutech Paravalvular Leak Device. The aim of this study was to evaluate early and midterm outcomes of percutaneous paravalvular leak closure utilising a novel occluder. METHODS AND
RESULTS: Twenty-one consecutive symptomatic patients who had moderate or severe paravalvular prosthetic regurgitation on transoesophageal echocardiography were included in the study. All the patients were clinically evaluated and found inoperable for surgery. They underwent transapical repair with the Occlutech Paravalvular Leak Device. The patients were followed for 17±5 months. Attempts were made to rectify 41 defects in 21 patients with 100% success. Mean procedure time was 76±40 min and fluoro-scopy time was 44±37 min. Early post-procedural outcome was uneventful in all cases, with ≥1 grade reduction in regurgitation in all of the patients. There was no mortality during hospital stay. There was one case of haemothorax in one patient and one case of pneumothorax in another. Post-implantation 90-day follow-up data were obtained for 19 patients, and 12-month data were obtained for 12 patients. No deaths due to any cause, stroke or surgery for prosthetic impingement, worsening or relapse of paravalvular leak during follow-up were recorded. One patient underwent reintervention and was treated successfully with the same occluder 11 months after the index procedure.
CONCLUSIONS: The novel Occlutech Paravalvular Leak Device, which was designed specifically for mitral and aortic paravalvular regurgitation, is an additional, useful tool in the device armamentarium for the treatment of PVL.

Entities:  

Mesh:

Year:  2016        PMID: 26897292     DOI: 10.4244/EIJV11I10A237

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  6 in total

Review 1.  Paravalvular Leaks-From Diagnosis to Management.

Authors:  Samuel Bernard; Evin Yucel
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-14

Review 2.  State-of-the-art Structural Interventions in Heart Failure.

Authors:  Jeffrey Park; Hussam S Suradi
Journal:  Card Fail Rev       Date:  2019-11-04

Review 3.  A comprehensive review of the diagnosis and management of mitral paravalvular leakage.

Authors:  Mustafa Ozan Gürsoy; Ahmet Güner; Macit Kalçık; Emrah Bayam; Mehmet Özkan
Journal:  Anatol J Cardiol       Date:  2020-12       Impact factor: 1.596

4.  Safety, Efficacy and Long-Term Outcomes of Patients Treated with the Occlutech Paravalvular Leak Device for Significant Paravalvular Regurgitation.

Authors:  Eustaquio Maria Onorato; Francesco Alamanni; Manuela Muratori; Grzegorz Smolka; Wojtek Wojakowski; Piotr Pysz; Aleksejus Zorinas; Diana Zakarkaite; Hélène Eltchaninoff; Pierre-Yves Litzer; François Godart; Patrick Calvert; Christos Christou; Abdurashid Mussayev; Bindo Missiroli; Igor Buzaev; Salvatore Curello; Tullio Tesorio; Antonio Luca Bartorelli
Journal:  J Clin Med       Date:  2022-04-01       Impact factor: 4.241

5.  EchoNavigator® technology facilitates transapical mitral paravalvular leak closure: a case report.

Authors:  Igor Vyacheslavovich Buzaev; Gulchachak Khalikova; Vladimir Vyacheslavovich Plechev; Eustaquio Maria Onorato
Journal:  Eur Heart J Case Rep       Date:  2021-06-05

6.  Fusion of real-time 3D transesophageal echocardiography and cardiac fluoroscopy imaging in transapical catheter-based mitral paravalvular leak closure.

Authors:  Aleksejus Zorinas; Vilius Janusauskas; Giedrius Davidavicius; Lina Puodziukaite; Diana Zakarkaite; Rita Kramena; Rasa Čypienė; Valdas Bilkis; Kestutis Rucinskas; Audrius Aidietis; Eustaquio M Onorato
Journal:  Postepy Kardiol Interwencyjnej       Date:  2017-09-25       Impact factor: 1.426

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.